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Abstract  
Heart disease is the number one cause of death in the United States. Despite the prevalence 
of heart failure in the population, little is known about its molecular mechanism of heart 
failure. The tight junction protein claudin-5 has recently become of interest to my lab and 
others in heart failure. Claudin-5 has been shown to localize to the lateral membrane of 
cardiomyocytes and claudin-5 is reduced in the hearts of the dko (dystrophin/utrophin 
knockout) mouse model of Duchenne Muscular Dystrophy, which exhibits the clinical 
signs of cardiomyopathy. Claudin-5 has also been shown to be reduced in at least 60% of 
human end-stage heart failure. When claudin-5 levels were maintained in the hearts of dko 
mice, much of the cardiomyopathy was prevented. These findings indicate that claudin-5 
is a potential therapeutic target for the treatment of cardiomyopathy and heart failure. To 
determine the mechanism between claudin-5 reduction and the development of 
cardiomyopathy, my lab developed an inducible cardiomyocyte-specific claudin-5 
knockdown mouse model, where claudin-5’s lone exon was excised using a Cre 
recombinase, which was activated by tamoxifen injection. At 14 weeks of age experimental 
mice and cre transgenic control mice exhibited reduced ejection fraction, indicating that a 
cre-dependent toxicity was occurring. To alleviate this issue, the mice were switched to 
tamoxifen citrate chow, which has been shown to cause less toxicity. At 14 weeks of age, 
experimental mice had an average ejection fraction of 57% while cre transgenic control 
mice had an average ejection fraction of 59%, which supports that the tamoxifen chow 
prevented the development of a Cre-dependent toxicity. The experimental mice have 
developed abnormal patterns in the basal lamina and they have developed areas of fibrosis 
in the extracellular matrix. Staining of an endothelial cell marker, CD31, shows that 
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experimental mice have developed abnormal wavy patterns of the endothelial cells. These 
findings indicate that claudin-5 is involved in the mechanical attachment of the 
cardiomyocytes to the extracellular matrix or to endothelial cells, since claudin-5 is also 
present in endothelial cells. This mouse model indicates that claudin-5 has a significant 
connection to the development of cardiomyopathy, which can be further explored using 
this model.  
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Introduction 
Dilated Cardiomyopathy 
Dilated Cardiomyopathy is one of the most common causes of heart failure. The 
estimated prevalence of dilated cardiomyopathy is 1:25001. There is a survival rate of less 
than 50% for patients who have exhibited dilated cardiomyopathy for greater than ten 
years. While the disease mostly affects those in their third and fourth decades, it can affect 
those of all ages1. This is a chronic illness that often leads to severe heart failure. Dilated 
cardiomyopathy results from an increase in the size of the left ventricle, which weakens 
the myocardium and prevents the heart from efficiently pumping, resulting in reduced 
ejection fractions16.  
There is no cure for dilated cardiomyopathy and the current standard of care is 
designed to prevent the progression of the disease. There are a variety of medications used 
to slow the disease. ACE (angiotensin-converting-enzyme) inhibitors and Angiotensin-II 
receptor antagonists are both designed to lower blood pressure, control the symptoms of 
heart failure, and slow the progression of the disease16. Beta-Blockers slow heart rate, 
which reduces the work load of the heart16. Calcium channel blockers increase the length 
of the resting phase of the heart by decreasing the amount of calcium entering the 
cardiomyocytes, also reducing the workload of the heart16. For more severe cases, 
pacemakers and ICDs (implantable cardioverter defibrillator) are implanted to control the 
heart rate and prevent arrhythmias16. For the most severe cases, heart transplants may be 
required.  
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Duchenne Muscular Dystrophy  
 Duchenne muscular dystrophy is one of the more severe forms of the muscular 
dystrophies. The average lifespan of those affected is around 25 years old. The disease 
affects boys, since it is X-linked recessive. Duchenne muscular dystrophy is caused by the 
loss of the dystrophin protein10. This destabilizes the muscle membrane and results in 
atrophy of muscles. Cardiomyopathy and respiratory failure are the most common causes 
of death13. 
 Duchenne muscular dystrophy is modeled in mice by two knockouts: mdx and dko. 
The mouse model has a mutation on the X chromosome, which results in a non-functional 
dystrophin protein. This model is genetically similar to the human disease. They develop 
weakness in muscles, but they do not develop many functional or histological signs of 
cardiomyopathy before six months of age20. The dko (or double-knockout) mouse has 
dystrophin and utrophin missing23. This mouse has a reduced lifespan and develops 
functional and histological signs cardiomyopathy by eight weeks of age7. They have 
decreased ejection fraction, increased left ventricle dilation, thinning of the ventricle and 
septum, and fibrosis occurs in their hearts2,7. My lab has studied the dko mouse model to 
determine gene expression changes that may account for the more severe pathology in dko 
compared to mdx hearts. They found that claudin-5, a transmembrane protein typically 
found in vasculature and endothelial cells, was reduced in dko mouse hearts21.  
Claudin-5  
 Claudin-5 is a transmembrane protein that is a component of tight junctions in 
endothelial tissue17. Knockouts of claudin-5 in mice result in neonatal death presumably 
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due to a size-selective loosening of the blood brain barrier19. However, the heart was never 
analyzed in this study. My lab discovered that claudin-5 also localized to the lateral 
membrane of cardiomyocytes21. They also found that claudin-5 is reduced in dko mouse 
hearts and this reduction results in an abnormal wavy pattern of the lateral membranes of 
cardiomyocytes21. This is particularly interesting, because out of the 24 different claudins, 
claudin-5 was the first to be found in the heart.  Only claudin-12 is also present in the heart, 
but only at very low levels8. My lab also found that claudin-5 is reduced in at least 60% of 
human end-stage heart failure15. Claudin-5 reduction was independent of connexin-43, 
which had previously been shown to be reduced in failing heart samples5. Claudin-5 was 
also reduced independent of dystrophin. This finding indicated that claudin-5 was involved 
in a novel pathway to end-stage heart failure. My lab showed that claudin-5 could be used 
to rescue cardiomyopathy in dko mice4. Claudin-5 levels in the dko mice were sustained 
using an adeno-associated virus.  They found that this expression prevented the 
development of the physiological and histological signs and symptoms of heart damage. 
Moving forward, my lab developed an inducible claudin-5 knockdown mouse model to 
determine if the reduction of claudin-5 alone could impair heart function.  
MerCreMer-Lox System 
 The claudin-5 knockdown mouse was developed using the MerCreMer-Lox 
system. An inducible, cardiomyocyte specific knockdown model was developed, which 
was designed to excise claudin-5’s lone exon from chromosome 16. Two loxP sites were 
inserted so that they flanked the claudin-5 exon. The Cre recombinase protein binds to 
these sites and excises the exon through deletion, inversion, or translocation. This “floxed” 
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construct was transfected into 129SV mouse embryonic stem cells. A neomycin antibiotic 
resistance cassette was inserted into the floxed construct to select cells containing the 
construct. Neomycin resistant cells were then screened for the correct homologous 
recombination event of the floxed construct replacing the wild-type claudin-5 allele.  These 
cells were implanted into the blastocysts from pregnant mice. The neomycin cassette was 
flanked by two FRT sites, which allowed for the removal of the neomycin cassette with the 
use of flp recombinase. The mice expressing the claudin-5 construct were bred with mice 
expressing the flp recombinase to remove the neomycin construct. Mice expressing the 
construct, without the neomycin cassette, were bred with mice expressing Cre 
recombinase. The Cre recombinase and Flp recombinase expressing mice were purchased 
from the Jackson laboratory18. This Cre recombinase is driven by the myosin heavy chain 
6 promoter, which drives expression of Cre recombinase to affect cardiomyocytes. The Cre 
recombinase was flanked by two mutated estrogen response elements (MerCreMer), which 
prevents Cre recombinase from entering the nucleus of the cell. These mutated estrogen 
response elements only respond to non-endogenous estrogen analogs, such as tamoxifen.  
The Cre recombinase is only able to enter the nucleus when the estrogen agonist tamoxifen 
binds to the mutated estrogen response elements. Once tamoxifen is either injected or 
ingested, the Cre recombinase enters the nucleus in cardiomyocytes and begins to excise 
the claudin-5 exon from chromosome 16.  
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Figure 1: Diagram of the target claudn-5 loxP allele to create claudin-5 knockdown mice. 
A mutated Cre recombinase binds to LoxP sites flanking the exon. This Cre recombinase 
is activated by estrogen agonists, such as tamoxifen, due to the presence of Mer sites around 
it. Once activated it moves to the nucleus and excises claudin-5 from chromosome 16. A 
neomycin cassette was present in the construct so that appropriate cells could be selected 
for, using antibiotic resistance. The neomycin cassette was removed using the Flp 
recombinase, which binds to the FRT sites flanking it.  
 
 Theoretically, homozygous floxed/floxed mice should be the experimental mice. 
However, there has never been a living, floxed/floxed experimental mouse with the neo 
cassette removed. There were floxed/floxed mice with the neo cassette present. However, 
the neo cassette interfered with the Cre excision, as is typical in many targeted alleles, 
preventing any reduction of claudin-5 from occurring. Since claudin-5 is a very small gene, 
the deletion of neo from the 3’ intron could potentially affect CDC45 whose 1st exon is 2.1 
kb downstream from Cldn5, which would result in the neonatal death of the floxed/floxed 
mice. CDC45 is required for postimplantation mouse development23. Heterozygous 
CDC45 knockouts live to a normal age and show no defects though. Heterozygous Cldn5 
flox cre+ do show a phenotype and are the experimental mice in this project. Heterozygous 
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Cldn5 flox cre+ mice are likely a better model for human heart failure, since claudin-5 is 
only reduced in human heart failure, rather than being completely gone.  
Methods  
Breeding 
All animal experiments were conducted under an approved IACUC protocol. 
Heterozygous Cre+ (Cldn5flox+/-; Cre+/-) were bred with wild type Cre- (Cldn5flox-/-; 
Cre-/-) mice. This produced litters with half heterozygous mice and half wild type mice. It 
also produced litters with 50/50 cre+ and cre- mice. This provided a variety of controls for 
the experimental heterozygous cre+ mice. However, this proportions became skewed to 
heterozygous mice, for some unknown reason. To reestablish the number of wild type 
mice, I backcrossed the line to C57 Black-6 (C57 BL/6) mice. This backcross was 
accomplished by mating heterozygous cre+ mice with C57 Bl/6 mice. This provided the 
correct proportions of genotypes (50/50 heterozygous/wild type and 50/50 cre+/cre-). Also, 
to easily track the litters of mice, each litter was named alphabetically. Thus the first litter 
born, under this naming system, was named Ariel and the next litter was named Baloo. All 
litters A-J were injected with tamoxifen, while all litters from K (Kanga) on were fed 
tamoxifen through their chow.  
Polymerase Chain Reaction 
Polymerase chain reactions were used to genotype the mice to determine which were 
experimental mice (heterozygous Cldn5 flox+/-; cre+/-, from here referred to as het cre+), 
control mice (heterozygous Cldn5 flox+/-; cre-/- (het cre-), wild type Cldn5 flox-/-; cre+/- 
(WT cre+), and wild type Cldn5 flox-/-; cre-/- (WT cre-)), and appropriate breeding mice. 
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At three weeks of age approximately a centimeter of tail was snipped from the mice and 
digested in 600 µl of TNES buffer (0.5 M Tris-HCL pH 7.5, 5 M NaCL, 0.5M EDTA, 10% 
Sodium dodecyl sulfate) and 17.5 µl of 20 mg/ml proteinase K. These were incubated 
overnight at 55°C in a rotating oven. If the tails did not digest after an overnight incubation, 
another 50 µl of proteinase K was added. Once the tails had fully digested, a salt-out 
extraction was used to isolate the DNA. 167 µl of 5 M NaCl was added to each tube. The 
tubes were shaken for 15 seconds. They were then centrifuged for 10 minutes, at 4°C, at 
14K rpm. The supernatant was poured into a new tube and 800 µl of 100% ice-cold ethanol 
was added to each tube and the samples were gently mixed. The DNA was then spooled 
onto a closed-end Pasteur pipette. The pipette was rinsed in 70% ethanol. The DNA was 
then resuspended in 300 µl 1X TE buffer (10 mM Tris-HCl pH 8.0, and 1mM EDTA) and 
incubated for 10 minutes at 65 °C to aid dissolution. They were stored in this buffer at 4 
°C. DNA was then genotyped using PCR reactions with the CreER primers (For: 
CCGGTCGATGCAACGAGTGAT, Rev: ACCAGAGTCATCCTTAGCGCC 59°C 
annealing temperature), 5’LoxP primers (For: ACCAGAGTCATCCTTAGCGCC, Rev: 
CGAAGTTATTAGGTCCCTCGACC 62°C annealing temperature), and wild type 
primers (For: GGAGAAGAACCTACTGAACCAAAGG, Rev: 
TCACCCAAGTTGCCATTCCC 59°C annealing temp). These primers detected the 
presence of the Cre transgene, the floxed construct, and the wild type product respectively. 
The PCR reaction contained 7.5 µl 2X Syzygy Taq master mix, 0.3 µl forward primer, 0.3 
µl reverse primer, 5.9 µl distilled water, and 1µl of DNA.  The products were separated by 
gel electrophoresis. ΦX HaeIII was used as the molecular weight marker. The presence of 
a PCR product at 798 bp indicated the presence of the Cre recombinase gene. The presence 
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of the 5’loxP product was determined by the presence of a ~600 bp product when the 
reaction was run with 5’loxP primers. This product indicated that at least one allele 
contained the 5’loxP construct. A wild type primer reaction was used to determine the 
presence of the wild type allele. The WT product was ~550bp. Heterozygous mice show 
two products, one for the WT product and one for the 3’loxP product. PCR reactions were 
visualized using 1% (5’LoxP and Cre PCRs) or 2% (wild type PCRs) agarose gels.  
Tamoxifen Injection 
At 4 weeks of age the mice were injected with tamoxifen (Sigma) in corn oil at 20 mg/ml. 
Each mouse was weighed before injection. The mice were administered 200 mg/kg per day 
of tamoxifen per weight. The tamoxfien was administered with a intra-peritoneal injection 
for 5 consecutive days.  
Tamoxifen Chow 
Due to toxicity issues, tamoxifen began to be administered by chow, rather than injection, 
as per discussion with the investigator who originally generated this Cre strain. The mice 
were still started at 4 weeks of age. There was 400 mg/g of tamoxifen citrate/kg Teklad 
Global 16% Protein Rodent Diet in chow. The mice were fed tamoxifen chow for two 
consecutive weeks, then switched to normal chow. The estimated dose per mouse was 40 
mg/kg per day. 
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Echocardiograms 
Each mouse underwent serial echocardiograms at 8 weeks of age, conducted by 
Mohammad Elnakish from Dr. Paul Janssen’s lab. These were used to calculate left 
ventricle mass/body weight ratios and ejection fractions.   
Dissections 
Mice were dissected at 14 weeks of age. A blood sample was taken and spun down to 
collect serum. The heart was then removed and cut transversely into two sections. The 
apical third was frozen in liquid nitrogen for homogenization. The top two thirds of the 
heart were frozen in OCT for histological sectioning. The lungs, liver, and kidney were 
then removed and frozen in liquid nitrogen. A quadriceps was removed and cut 
transversely. One section was frozen in liquid nitrogen for homogenization and another 
was frozen in OCT for sectioning. The OCT samples were cut in to 8 µm sections using a 
cryostat, mounted on slides, and stored at -80 °C. 
Tissue Analysis 
Immunofluorescence  
Heart sample slides were brought to room temperature and the sections were encircled with 
a hydrophobic pen to form a barrier. The slides were equilibrated in potassium phosphate 
buffered solution (KPBS-K2HPO4, KH2PO4, NaCl) for 5 minutes. They were blocked with 
KPBS + 1% gelatin for 15 minutes. They were rinsed with KPBSG (KPBS + 0.2% gelatin) 
for 5 minutes. They were incubated in 100 µl of the antibody of choice (see Table 1) for 2 
hours, at room temperature, in a wet chamber. The antibody was diluted to the appropriate 
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dilution with KPBSG and 1% normal goat serum (NGS). The slides were rinsed for 5 
minutes 3 times in KPBSG. 100 µl of the secondary antibody was then applied and the 
slides were incubated for 1 hour, at room temperature, in a wet chamber, in the dark. The 
secondary antibody was diluted to the appropriate dilution with KPBSG and 1% normal 
goat serum. The slides were then washed with KPBSG for 5 minutes 3 times. The slides 
were mounted with 35 µl vectashield and DAPI (at 2 µg/ml) and coverslipped. The slides 
were stored in a -20 °C frost free freezer. The sections were visualized using the Nikon 
Eclipse 800 microscope with an epifluorescence mercury lamp. The exposure time was 
determined based on the positive and negative control slides so that the staining could be 
seen, without being overly bright and kept consistent between all slides for a given 
experiment.  
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Table 1: Primary Antibodies used for immunofluorescent staining.  
Antibody 
(Species) 
Company Dilution 
Other 
Specifications 
Claudin-5 
(rabbit) 
Abcam 1:200 
None 
Ephrin-B1 
(goat) 
R&D Systems 1:25 
Fetal Bovine 
Serum was used 
instead of NGS 
Tenascin 
(rabbit) 
Millipore 1:100 
None 
Fibronectin 
(rabbit) 
Abcam 1:40 
None 
Collagen 
(rabbit) 
Abcam 1:100 
None 
CD-31 
(rabbit) 
Abcame 1:50 
None 
 
Collagen Quantitation  
The amounts of collagen scarring was quantitated by measuring the immunoreactive area 
using Photoshop. 4x images were composited together in Photoshop and then fibrotic areas 
were selected and marked red. Using the histogram function in Photoshop, the percentage 
of red colored areas was calculated. This percentage represents the percentage of the heart 
section that contained collagen and values above control, which supports the presence of 
fibrosis.  
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Hematoxylin and Eosin Staining 
Heart sample slides were also stained with hematoxylin and eosin to examine the structure 
and integrity of the heart tissue. The slides were fixed in 100% ethanol for 30 sec at room 
temperature. They were washed in tap water. The slides were then stained in hematoxylin 
for 30 sec to stain cell nuclei, then the slides were washed in tap water. They were stained 
in eosin for 20 sec to stain the cytoplasm of cells, then the slides were washed in tap water. 
They were then dehydrated in 100% ethanol, 90% ethanol, and 70% ethanol and then they 
were washed with histochoice clearing agent. The slides were then mounted with cytoseal 
and coverslipped. The slides were visualized using a light microscope. Composite pictures 
were taken at 4X magnification. The individual photos were composited together using 
Adobe PhotoShop.  
Transmission Electron Microscopy (TEM) 
An approximately 1 mm by 1 mm cube of the ventricle of the heart was taken from six 
mice (2 het cre +, 2 het cre-, 2 WT cre +). This cube was fixed in 3% glutaraldehyde and 
4% PFA (25% glutaraldehyde, 4.5% PFA in 0.1M sodium phosphate pH 7.4) for 1 hour. 
The cube was then fixed in 3% glutaradehyde (25% glutaraldehyde in 0.1M sodium 
phosphate pH 7.4). The samples were then processed and image by the Campus 
Microscopy and Imaging Facility (CMIF) and viewed on a G2 Spirit TEM by an FEI 
technician.  
Subcellular Fractionations 
Whole hearts were weighed and resuspended in 7.5 x volume of homogenization buffer 
(20mM sodium pyrophosphate, 20mM sodium phosphate monobasic, 1 mM MgCl2, 303 
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mM sucrose, 0.5 mM EDTA, HCl to raise pH to 7.1, leupepetin, pepstatinA, benzamidine, 
PMSF). The hearts were homogenized using a small homogenization probe. Between each 
sample the probe was rinsed twice with distilled water and detergent, just distilled water, 
and ethanol. Samples were centrifuged at 14,000 g at 5 °C for 15 minutes. The supernatant 
was pipetted off and transferred to another tube, where homogenization buffer was added 
until there was 2 ml of solution. Each tube was balanced to be the same weight and 
centrifuged for 37 minutes at 142,000 x g in a S55S Ti rotor in an ultracentrifuge cooled to 
4 °C. The supernatant was pipetted off and then the pellets were resuspended in 2 ml of 
KCl-Wash buffer (0.6 M KCl, 0.3 M sucrose, 50 mM Tris-Cl pH 7.4, 0.1 mM PMSF, 0.75 
mM benzamidine). Each tube was balanced to be the same weight. The samples were spun 
for 37 minutes, at 4 °C, at 142,000 x g using the S55S Ti rotor in an ultracentrifuge. The 
supernatant was poured off and the pellets were resuspended in 50 µl of resuspension buffer 
(10 mM sodium phosphate pH 7.8, 5 mM EDTA, 150 mM NaCl, leupeptin, pepstatinA, 
benzamidine, PMSF). These purified microsomes were stored at -80 °C.  
Results  
At 8 weeks of age the echocardiograms of mice injected with tamoxifen showed 
reduced ejection fraction for het cre + (52.97%) and wt cre + (46.93%) mice compared to 
het cre – (68.97%) mice (see ﬁgure 2). This indicated that the tamoxifen injection treatment 
resulted in some form of cre-dependent toxicity, which was detrimental to whole heart 
function. After these results, the mice were switched to tamoxifen chow, which has been 
shown to alleviate toxicity issues11. At 14 weeks of age het cre+ mice had an average 
ejection fraction of 57.3%, which is lower than any other genotype, including wt cre+ 
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(59.1%) (see figure 3). Excision PCR was performed by another member of my lab, which 
showed that tamoxifen chow claudin-5 excision was as efficient as tamoxifen injection 
claudin-5 excision. Longitudinal echoes on the same mice are underway.  
Figure 2: Ejection fractions of tamoxifen injected CKD mice at 8 weeks. Both wild type 
cre+ and heterozygous cre+ mice show reduced ejection fraction at 8 weeks of age. This 
indicates that the tamoxifen treatment produced a cre-dependent toxicity. 
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Figure 3: Ejection fractions of tamoxifen-chow mice at 14 weeks of age. The het cre+ 
mice have an average ejection fraction of 57%, which is lower than any other genotype. 
  
Hematoxylin and Eosin staining was used to create composites of whole mouse 
hearts. Comparison of these composites showed that the tamoxifen injected het cre+ mice 
had dilated hearts, with thinner walls (see figure 4). This finding has not been replicated 
yet by the tamoxifen chow fed mice and may have been caused by the tamoxifen toxicity.  
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Figure 4: Hematoxylin and eosin staining of claudin-5 knockdown by tamoxifen injection 
mouse hearts. The heterozygous cre+ heart is dilated, with thin walls and much irregularity 
in the papillary muscle structure. This has not been replicated with tamoxifen chow fed 
mice and may have been due to tamoxifen injection toxicity.  
 
Claudin-5 immunoﬂuorescence staining on 14 week old CKD mouse hearts showed 
a reduction of claudin-5 in the membranes of cardiomyocytes (see figure 5). Similar results 
are observed with both tamoxifen delivery methods. Claudin-5 was still normally 
expressed in vessels. The reduction in claudin-5 occurred in a mosaic pattern, with certain 
regions aﬀected more severely than others. This is likely due to the fact that Cre excision 
of the claudin-5 allele is a stochastic event and may not occur in every cardiomyocyte.  
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Figure 5: Claudin-5 immunofluorescence staining on CKD mouse hearts. Claudin-5 has 
been reduced in the cardiomyocytes of the heart, but it is unaffected in the large vessels.  
 
Ephrin-B1 is a transmembrane protein that has been found to bind with claudin-5 
in cardiomyocytes6. Ephrin-B1 immunoﬂuorescence staining showed that ephrin-B1 was 
also mosaically reduced in the lateral membrane of cardiomyocytes, in a pattern similar to 
claudin-5 (see figure 6). This indicates that ephrin-B1 stability requires claudin-5 and the 
two likely form a complex in the lateral membrane of cardiomyocytes. 
Fibronectin is an extracellular matrix protein. In 14 week old CKD mouse hearts, 
ﬁbronectin staining showed areas of irregular staining in the het cre+. There were many 
regions in the heart that had increased ﬁbronectin staining in a scarring pattern (see figure 
6). This indicates that the loss of claudin-5 allows the extracellular matrix to proliferate 
and scarring to occur. Other extracellular matrix proteins were also shown to have a similar 
pattern of staining in the het cre+ mice. Tenascin and collagen showed a very similar 
staining pattern to fibronectin. Composites of the whole heart were made for the collagen 
staining and the percentage of areas of scarring was quantitated (see figure 7). The het cre+ 
mice had a higher percentage of scarring in the collagen quantifications. 
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Figure 6: Immunofluorescence of CKD mice at 14 weeks of age. The top row is ephrin-
B1 staining, which shows a reduction in the heterozygous cre+ mice at the cardiomyocytes. 
Ephrin-B1 was reduced in a mosaic fashion, similar to claudin-5. This is likely because the 
Cre excision is a stochastic event, which may not occur in every cardiomyocyte. The 
middle row is fibronectin staining, which illustrates the abnormal structure of the 
extracellular matrix. The heterozygous cre+ mice shows increased areas of scarring and 
irregular staining. The bottom row is tenascin, which is another extracellular matrix 
protein. This staining shows the same pattern as fibronectin, with increased areas of 
scarring in the heterozygous cre+ mice. Two het cre+ mice are shown to show the range in 
staining between our experimental mice.  
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Figure 7: Collagen Quantification. The percentage of collagen scarring in the heart was 
calculated. Heterozygous cre+ mice had an increased percentage of scarring, compared to 
the other genotypes, including wild type cre+. This indicates that some fibrosis occurs in 
the knockdown mouse hearts, which is comparable to other mouse models of 
cardiomyopathy.  
      
 
Transmission electron microscopy imaging on 14 week old CKD mouse hearts 
showed irregular patterning for the het cre + mice at the basement membrane. The 
membrane had lost electron density and normal basal lamina structure. Also, the 
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extracellular space between cells appeared increased. All other genotypes of mice appeared 
normal (see ﬁgure 8). 
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CD31 immunofluorescence is used to stain the endothelial cells in the vasculature 
in the heart. CD31 positive cells are shed from human cardiovascular disease into the 
bloodstream14. Since claudin-5 is present in both endothelial cells and cardiomyocytes 
claudin-5 may form a junction with CD31 positive cells. Therefore we examined CD31 
immunofluorescence in the CKD heart samples. Our preliminary data may indicate that 
CD31 is slightly reduced in the het cre+ mice. Specifically, the microvasculature appears 
reduced and longitudinal regions show a waviness of the CD31 cells (see figure 9). This 
staining is similar to CD31 staining in dko mouse hearts, which exhibit cardiomyopathy 
(JRF lab, unpublished data).  The abnormal membrane pattern matches the alterations in 
the basement membrane seen in the transmission electron microscopy.  
Figure 9: Immunofluorescence staining of CD31 on CKD mouse hearts. CD31 is a marker 
of endothelial cells, particularly in the vasculature. Het cre+ mice show a reduction in 
microvasculature (the small circles). The het cre+ mice have also developed an abnormal 
wavy pattern in the longitudinal areas. In general, the CD31 staining is dimmer in the het 
cre+ mice, which indicates that CD31 positive cells may have been lost.  
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Discussion  
 The histological data shown here indicates that claudin-5 reduction results in major 
alterations to the basal lamina and extracellular matrix. These alterations are similar to 
those seen in the dko mouse model, which develops cardiomyopathy. Claudin-5 reduction 
may also result in CD31+ cell shedding; however this data is very preliminary and requires 
replication. These findings support my hypothesis that claudin-5 is necessary to maintain 
normal heart function and that claudin-5 reduction is a major step in the development of 
cardiomyopathy. While claudin-5 reduction alone has not yet caused reduced ejection 
fraction, a trend is beginning to appear and echocardiograms done at further time points 
may show reduced ejection fractions.  This study shows the importance of examining the 
relationship between claudin-5 reduction and the development of cardiomyopathy. This 
study has shown that claudin-5 reduction is not simply correlated with cardiomyopathy, 
but that likely claudin-5 reduction is a step in the development of heart failure. While my 
lab showed that claudin-5 protein levels are reduced in end-stage human heart failure15, 
recently claudin-5 gene expression was also shown to be reduced in human heart failure12. 
This mouse line can be used to further examine the relationship between claudin-5 and 
cardiomyopathy.  
 While the tamoxifen injected mice developed dilated hearts and had reduced whole 
heart function, this phenotype was likely due to a Cre-dependent toxicity, since both het 
cre+ and wt cre+ mice developed the phenotype. Tamoxifen citrate chow has been shown 
to be as effective as tamoxifen injection, while causing significantly less stress to the 
mice11. By switching our mice from tamoxifen injection to tamoxifen chow, we were able 
to alleviate the Cre-dependent toxicity. The tamoxifen chow mice develop a phenotype 
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more slowly than the tamoxifen injected mice. This is likely due to the fact that the 
tamoxifen chow mice are fed chow for two weeks, rather than one week of injection. Also, 
the slower development of a phenotype mimics the development of human cardiomyopathy 
more similarly. We will continue to perform longitudinal echocardiograms on the 
tamoxifen chow mice to determine if they develop reduced ejection fraction.  
 We still have to confirm why no floxed/floxed mice have been found in this mouse 
line. I will perform real-time quantitative PCR on these mice to test gene expression levels 
of claudin-5 and CDC45, a gene downstream of claudin-5 that may have been affected by 
the removal of the neo cassette. CDC45 is known to result in pre-implantational prenatal 
mortality24. Real-time PCR will also quantitatively show how much claudin-5 reduction 
we have achieved in this mouse model and allow us to compare this to the gene expression 
alterations in human heart failure.  
I will also further analyze the cellular alterations quantitatively. Western blot 
analysis on subcellular fractions and isolated cardiomyocytes will allow me to examine 
claudin-5, ephrin-B1, and CD31 protein levels in both isolated membranes and 
cardiomyocytes. These experiments will provide quantitative support for the qualitative 
data shown here.  
Lastly, additional studies of the effect of claudin-5 reduction on whole heart 
function can be performed. We will begin stressing the mice, using a β-adrenergic agonist, 
to determine if additional stress will exacerbate the phenotype. We can do a Kaplan-Meier 
survival analysis, to determine the effect of claudin-5 reduction on survival time, both with 
and without stress.  
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 Both immunofluorescence and TEM indicate that claudin-5 reduction results in the 
development of abnormalities in the extracellular matrix. This indicates that claudin-5 
could be involved with the mechanical attachment of the cardiomyocyte to the extracellular 
matrix. The reduction of claudin-5 would allow the cardiomyocytes to “slip” off of the 
matrix and then the matrix could begin to expand. This mechanism is supported by data 
shown in ephrin-B1 knockout mice. Ephrin-B1 is proposed to bind with claudin-5 and 
ephrin-B1 knockout mice have reduced claudin-5 and faulty matrix adhesion6. Another 
possible hypothesis is that claudin-5 binds to CD31+ cells, since claudin-5 is also present 
in endothelial cells. The loss of claudin-5 could destabilize the CD31+ cells and lead to the 
shedding of CD31+ cells into the bloodstream. After the CD31+ cells were lost, then the 
extracellular matrix would begin to proliferate and fibrosis could occur. To examine this 
mechanism, we plan to use flow cytometry to sort cells in the serum of this mouse line and 
to search for shed CD31+ cells.  
Conclusion 
 The claudin-5 knockdown mouse model could potentially become a model for 
human dilated cardiomyopathy. These mice show many biochemical alterations similar to 
cardiomyopathy. This mouse line will be useful for future experiments examining the 
molecular mechanism behind the development of dilated cardiomyopathy. This mouse line 
also further supports the hypothesis that claudin-5 is necessary to maintain whole heart 
function. This mouse model can be used to develop various therapeutic targets and to 
further examine the therapeutic role of claudin-5.  
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